Shannon M. Lentz is a counsel in the Intellectual Property Group in the firm's Washington, D.C. office. Her practice includes all aspects of patent law, including preparing and prosecuting patent applications; providing infringement and validity opinions; counseling in litigation and post-grant proceedings; and participating in inter partes review proceedings.
Shannon has experience with a wide range of biomedical and chemical technologies, including cell and molecular biology, genetics, organic chemistry, pharmaceutical chemistry, polymer chemistry, metallurgy, medical devices, biologics, coatings, adhesives, nanomaterials, research tools, and drug delivery technologies.
Prior to becoming an attorney, Shannon worked in the Functional Genomics group of the Biological Defense Research Directorate of the Naval Medical Research Center.
Shannon graduated from the University of Maryland, College Park with a B.S. in molecular biology and genetics. She received her J.D. from the University of Maryland School of Law.
Representative Cases
- Representing LifeNet Health in a five-patent case against Surgalign (f/k/a RTI Surgical) involving soft tissue grafts and spinal implants, successfully defending LifeNet Health’s patents against IPR petitions filed by Surgalign.
- Represented inventors in a highly contested patent inventorship bench trial in the Central District of California and subsequent appeal to the Federal Circuit involving a pharmaceutical compound.
- Moderna v. CureVac: Represented patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
- Apotex v. Amgen, IPR2016-01542 (PTAB): Represented petitioner Apotex in an inter partes review successfully invalidating a patent relating to Neupogen® and Neulasta®.
- LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal.
- Represented university system in patent license dispute over cancer treatment in which the plaintiff pharmaceutical company sought damages exceeding $200 million. Obtained summary adjudication in favor of client.
Affiliations
Admitted to practice: District of Columbia, Maryland, U.S. Patent and Trademark Office (USPTO).
Highlights, News & Knowledge
Client Alerts & Newsletters
-
"After Arthrex Decision, Interim USPTO Guidance Allows Straight-to-Director Review of Any Issue in an IPR,"
IP Insights
(July 2, 2021).
Contacts: Vincent J. Galluzzo, Laura A. Lydigsen, Joshua James, Shannon Lentz
-
"Supreme Court’s recent decision in US v. Arthrex found that Section 6(c) of the AIA was unconstitutional,"
(June 24, 2021).
Contacts: Vincent J. Galluzzo, Shannon Lentz
-
"U.S. Patent Applicants Can Now Expedite Appeals Under New Pilot Program,"
IP Insights
(July 6, 2020).
Contacts: Deborah H. Yellin, Shannon Lentz
Media Mentions
Firm News & Announcements